SINGLE-CHAIN ANTIGEN-BINDING PROTEIN THAT BINDS CEA I

Genex的科学家开发了专有技术用于 抗体可变区编码基因的设计 通过多肽连接物连接的分子。这两种基因都有编码 VL和VH区域，所产生的蛋白质被合成为 大肠杆菌中的单链多肽链。经过提纯和 单链抗原结合蛋白(SCABP)的复性， 从一种专利的抗牛生长激素(BGH)中提取 单抗，与GBH特异性结合。在第一阶段， 抗BGH SCABP将转化为抗BGH 癌胚抗原(CEA)SCABP 来自抗CEA的互补决定区(CDR) 通过以下方式将单抗导入SCABP框架 寡核苷酸定向诱变。反CEA的SCABP将 然后在大肠杆菌中表达，并对蛋白质进行纯化， 重新折叠并进行活性检测。在第二阶段，抗CEA SCABP将作为一种新的成像和治疗模型。 产生CEA的肿瘤。

Genex scientists have developed proprietary technology for the design of genes which code for the variable regions of antibody molecules linkded by polypeptide linkers. The genes code for both VL and VH regions and the resulting protein is synthesized as a single polypeptide chain in E. coli. After purification and refolding the single-chain antigen binding protein (SCABP), derived from a proprietary anti-bovine growth hormone (BGH) monoclonal antibody, binds specifically to GBH. During Phase I, the anti-BGH SCABP will be converted to an anti- carcinoembryonic antigen (CEA) SCABP by inserting the complementarity-determining regions (CDRs) from an anti-CEA monoclonal antibody into the SCABP framework by oligonucleotide-directed mutagenesis. The anti-CEA SCABP will then be expressed in E. coli, and the protein will be purified, refolded and assayed for activity. In Phase II, the anti-CEA SCABP will be used as a model for the imaging and therapy of tumors which produce CEA.